New drug combo shows promise in early pancreatic cancer trial
NCT ID NCT05546853
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested whether adding a new drug called NP137 to standard chemotherapy (mFOLFIRINOX) is safe and could help shrink tumors in people with locally advanced pancreatic cancer that cannot be removed by surgery. 43 participants received the combination. The main goal was to check side effects, and researchers also looked at tumor response and survival. Results are preliminary and need further study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NP137 (a drug) combined with standard chemotherapy (mFOLFIRINOX)
What this could lead to
If successful, this combination could improve tumor shrinkage and survival for people with locally advanced pancreatic cancer.
What could go wrong
This is a very early Phase 1 trial with only 43 people, so safety and effectiveness are not yet proven. The added drug may cause more side effects without clear benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AP-HP Pitié Salpetrière
Paris, 75013, France
-
CHRU Lille
Lille, 59037, France
-
CHU Poitiers
Poitiers, 86000, France
-
CHU Rennes
Rennes, 35033, France
-
CHU St Etienne
Saint-Etienne, 42055, France
-
CHU de BORDEAUX
Bordeaux, 33404, France
-
CHU de GRENOBLE ALPES
Grenoble, Alpes, 38043, France
-
CHU de REIMS
Reims, 51092, France
-
Hôpital Privé Jean Mermoz
Lyon, 69008, France